Company Analysis

Immunovant, Inc. (IMVT)

Nasdaq: IMVT · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2019
Grade5.8
◀ Past 5.5● Present 5.0▶ Future 6.5
6 est.

Who runs Immunovant, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Venker Eric
Chief Executive Officer. First filing Feb 2020, latest Oct 5, 2026, 3 filings in all.
Officers reporting now
6
of 13 people with a filing in the last fifteen months
Directors reporting now
7
33 people on the record since 2019
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Girao TiagoChief Financial OfficerApr 2025Oct 30, 20264 · $1.6M
Stout Jay SChief Technology OfficerApr 2023Oct 23, 202616 · $2.4M
Gloria MelanieChief Operating OfficerNov 2024Oct 9, 202615 · $1.7M
Van Tuyl ChristopherChief Legal OfficerDec 2024Oct 9, 202611 · $1.5M
Venker EricChief Executive OfficerFeb 2020Oct 5, 20264 · $600,000
Geffner MichaelChief Medical OfficerJan 2024Oct 24, 2025none
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Pande AtuldirectorDec 2019Nov 12, 20266 · $500,000
Fromkin Andrew J.directorDec 2019May 29, 20264 · $8.0M
Susman Robert GrahamdirectorApr 2025May 1, 20261 · $100,000
Bauer JakedirectorApr 2025Apr 9, 2026none
Hughes Douglas J.directorDec 2019Apr 9, 20262 · $300,000
Torti FrankdirectorDec 2019Apr 9, 2026none
Roivant Sciences Ltd.directorDec 2019Dec 12, 2025none
Earlier names on the record21, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IMVT · research, not advice